Castle Biosciences

251 articles with Castle Biosciences

• Castle Biosciences' Mesothelioma Molecular Test Accurately Stratifies Survival Risk Under Surgical And Non-Surgical Treatment Plans

  4/29/2014

• Castle Biosciences Announces Data Demonstrating Ability To Identify Esophageal Cancer Patients Resistant To Standard Pre-Surgical Treatment Of Chemotherapy And Radiation

  1/16/2014

• Castle Biosciences Launches Tissue Repository for Eye Cancer Patients

  9/30/2013

• Castle Biosciences Genetic Test Highly Accurate in Differentiating Thymomas From Thymic Carcinoma Tumors

  9/25/2013

• Castle Biosciences Release: Gene Test Identifies Non-Metastatic Melanoma Patients at High Risk of Recurrence

  8/5/2013

• Castle Biosciences Release: New Website Dedicated to Patients With Thymic Cancer

  7/30/2013

• Castle Biosciences Release: Gene Test Highly Accurate in Predicting Metastasis in Patients With Thymoma

  7/25/2013

• Castle Biosciences Announces Availability of DecisionDx-Melanoma Test to Identify Stage I & II Melanoma Patients at High Risk of Metastasis

  6/3/2013

• Castle Biosciences Licenses Thymoma Test Technology; Availability on Track for End of 1st Quarter of 2012

  1/25/2012

• Castle Biosciences Announces Availability of DecisionDx-GBM Biomarker Test for Brain Cancer (Glioblastoma Multiforme) Patients that Predicts Overall Survival to First-Line Standard of Care Treatment

  7/16/2009

• Castle Biosciences, a Biomarker Based Cancer Diagnostics Company, Announces Appointment of Derek Maetzold as President and CEO

  9/26/2008